Cite
HARVARD Citation
Maciocia, N. et al. (2017). Real‐world use of pomalidomide and dexamethasone in double refractory multiple myeloma suggests benefit in renal impairment and adverse genetics: a multi‐centre UK experience. British journal of haematology. pp. 908-917. [Online].